GT200900123A - Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace - Google Patents
Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlaceInfo
- Publication number
- GT200900123A GT200900123A GT200900123A GT200900123A GT200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- methods
- inhibit
- interaction
- link molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900123A true GT200900123A (es) | 2011-09-02 |
Family
ID=39064388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900123A GT200900123A (es) | 2006-11-15 | 2009-05-12 | Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7842815B2 (https=) |
| EP (1) | EP2094673B1 (https=) |
| JP (2) | JP2010510214A (https=) |
| KR (1) | KR101530721B1 (https=) |
| CN (1) | CN101583606B (https=) |
| AU (1) | AU2007319848B2 (https=) |
| BR (1) | BRPI0718606A2 (https=) |
| CA (1) | CA2669596C (https=) |
| EC (1) | ECSP099398A (https=) |
| ES (1) | ES2537762T3 (https=) |
| GT (1) | GT200900123A (https=) |
| IL (1) | IL198597A (https=) |
| MA (1) | MA31067B1 (https=) |
| MX (1) | MX2009005184A (https=) |
| MY (1) | MY156754A (https=) |
| NO (1) | NO20092306L (https=) |
| NZ (1) | NZ577243A (https=) |
| RU (1) | RU2449996C2 (https=) |
| TN (1) | TN2009000182A1 (https=) |
| WO (1) | WO2008060569A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| KR20100126361A (ko) * | 2008-02-08 | 2010-12-01 | 에일러론 테라퓨틱스 인코포레이티드 | 치료용 펩티드유사 거대고리 |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| WO2013119579A1 (en) | 2012-02-06 | 2013-08-15 | Discoveryx Corporation | Detection of intracellular binding events by measuring protein abundance |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
| US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| RU2726367C2 (ru) | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| ES2931533T3 (es) * | 2017-04-05 | 2022-12-30 | Harvard College | Compuesto macrocíclico y usos del mismo |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| ATE181735T1 (de) * | 1993-05-01 | 1999-07-15 | Merck Patent Gmbh | Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten |
| BR9408137A (pt) | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
| ATE169009T1 (de) | 1994-03-09 | 1998-08-15 | Pfizer | Isoxazoline verbindung zur hemmung tnf-freigabe |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU4064597A (en) | 1996-08-16 | 1998-03-06 | Du Pont Pharmaceuticals Company | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| JP2002518985A (ja) | 1997-05-07 | 2002-06-25 | ユニバーシティー・オブ・ピッツバーグ | タンパク質イソプレニルトランスフェラーゼの阻害剤 |
| WO2001016115A1 (en) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| AU2002305769B2 (en) | 2001-05-30 | 2007-07-19 | Georgetown University | Small molecule antagonists of Bcl2 family proteins |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| ATE548359T1 (de) | 2004-06-17 | 2012-03-15 | Infinity Discovery Inc | Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern |
| US20060020004A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/en active Active
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active Expired - Fee Related
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/en not_active Ceased
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 CA CA2669596A patent/CA2669596C/en not_active Expired - Fee Related
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007319848B2 (en) | 2012-05-03 |
| KR101530721B1 (ko) | 2015-06-22 |
| JP2014055156A (ja) | 2014-03-27 |
| US20110160259A1 (en) | 2011-06-30 |
| RU2009121808A (ru) | 2010-12-20 |
| KR20090082284A (ko) | 2009-07-29 |
| HK1130057A1 (en) | 2009-12-18 |
| NO20092306L (no) | 2009-08-17 |
| US8461191B2 (en) | 2013-06-11 |
| IL198597A (en) | 2014-03-31 |
| EP2094673B1 (en) | 2015-04-08 |
| CN101583606B (zh) | 2015-04-08 |
| JP2010510214A (ja) | 2010-04-02 |
| CN101583606A (zh) | 2009-11-18 |
| MX2009005184A (es) | 2009-10-12 |
| US7842815B2 (en) | 2010-11-30 |
| ECSP099398A (es) | 2009-07-31 |
| US20080306127A9 (en) | 2008-12-11 |
| CA2669596C (en) | 2014-09-30 |
| AU2007319848A1 (en) | 2008-05-22 |
| ES2537762T3 (es) | 2015-06-11 |
| EP2094673A1 (en) | 2009-09-02 |
| WO2008060569A1 (en) | 2008-05-22 |
| US20070161690A1 (en) | 2007-07-12 |
| CA2669596A1 (en) | 2008-05-22 |
| MA31067B1 (fr) | 2010-01-04 |
| BRPI0718606A2 (pt) | 2013-12-17 |
| MY156754A (en) | 2016-03-31 |
| TN2009000182A1 (en) | 2010-10-18 |
| RU2449996C2 (ru) | 2012-05-10 |
| NZ577243A (en) | 2011-12-22 |
| IL198597A0 (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200900123A (es) | Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace | |
| ECSP088607A (es) | Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión | |
| GT200600328A (es) | Derivados de isoquinolona sustituidos con piperidinilo | |
| CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| GT200600327A (es) | Ciclohexilaminoisoquinolona | |
| GT200900183A (es) | Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina | |
| UY30840A1 (es) | Derivados de isoquinolina e isoquinolinona sustituidos | |
| GT201000376A (es) | Compuestos organicos | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
| GT200800187A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| UY30843A1 (es) | Derivados de isoquinolona sustituidos con ciloalquilamina | |
| CL2007002424A1 (es) | Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer. | |
| GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
| ECSP088103A (es) | Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia | |
| CR10138A (es) | 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| SV2010003650A (es) | INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA | |
| ECSP10010705A (es) | Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| GT200800102A (es) | Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
| DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos |